

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
- Clearly defined error bars
State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on [statistics for biologists](#) may be useful.

Software and code

Policy information about [availability of computer code](#)

Data collection

FLASH v1.2.11, cutadapt 1.14, Python 2.7.9, and FASTX-toolkit 0.0.14 were used for sequence reconstruction and cleanup. EPU Automated Data Collection Software and Legion v3.2 were used for cryo-EM data collection.

Data analysis

Partis, FastTree 2, Prune.py, PHYLIP v3.696, BEAST v1.8.4, RevBayes, and Ecgtheow were used for sequence analysis. ForteBio's Octet Software Data Analysis 7.0, Prism 7.0c, and FlowJo 10 were used for binding assays. PyMOL, Legion v3.2, Relion v2.1, Chimera v1.13, MUSTER, MotionCor2 v1.0.4, and CTFIND4 v4.1.8 were used in cryo-EM data analysis. Unpublished custom code (prune.py and ecgtheow) have been made publicly available via GitHub, links are included in the manuscript.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/authors/policies/ReportingSummary-flat.pdf](https://www.nature.com/authors/policies/ReportingSummary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| | |
|-----------------|---|
| Sample size | Our sample size was one individual because this infant mounted broad and potent antibody responses to HIV. |
| Data exclusions | No data were excluded from this study. |
| Replication | We replicated the deep sequencing of our subject's antibody genes. Beyond technical replicates, we replicated all neutralization assays with different stocks of pseudovirus and different individuals performing the assays. |
| Randomization | We had no randomization in this study of one individual's antibody response. |
| Blinding | Blinding was not relevant to our study because we had no randomization groups. |

Reporting for specific materials, systems and methods

Materials & experimental systems

| n/a | Involved in the study |
|-------------------------------------|---|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Unique biological materials |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Human research participants |

Methods

| n/a | Involved in the study |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Unique biological materials

Policy information about [availability of materials](#)

Obtaining unique materials The longitudinal blood samples collected from infant BF520 were used in this study and previous studies, so none are available. There are no duplicate samples in existence.

Antibodies

| | |
|-----------------|---|
| Antibodies used | Human BF520.1 GenBank: KX168065, KX168069. Antibody sequences for the inferred BF520.1 lineage intermediates, inferred naïves, and minimal mutants are available from the corresponding author upon request. As these sequences were inferred, they are not eligible for deposition into GenBank. |
| Validation | No validation of this antibody lineage was required. Simonich, Cell 2016 describes the discovery of antibody BF520.1. |

Eukaryotic cell lines

Policy information about [cell lines](#)

| | |
|--|--|
| Cell line source(s) | 293F (Invitrogen R79007), TZM-bl (NIH-ARP 8129) |
| Authentication | None of these cell lines were authenticated upon receipt from primary sources. We are able to authenticate them if required. |
| Mycoplasma contamination | All cell lines tested negative for mycoplasma. |
| Commonly misidentified lines (See ICLAC register) | None used |

Human research participants

Policy information about [studies involving human research participants](#)

| | |
|----------------------------|---|
| Population characteristics | We studied one individual human participant from the Nairobi Breastfeeding Clinical Trial cohort (Nduati, JAMA, 2000). |
| Recruitment | This participant was recruited according to the procedures outlined in Nduati, JAMA, 2000. Infant BF520 was in utero during enrollment of the mother-infant pair. |